HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

(1- (hydroxymethyl)- 4- (4- methyl- 3- (methylethyl)pentylidene)- 3- oxo- 2- oxolanyl)methyl 4-methyl-3-(methylethyl)pentanoate

binds protein kinase C; structure in first source

Also Known As:

DAG-lactone

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Lactones: 1549
  - 4-Butyrolactone: 81
    - (1-(hydroxymethyl)-4-(4-methyl-3-(methylethyl)pentylidene)-3-oxo-2-oxolanyl)methyl 4-methyl-3-(methylethyl)pentanoate: 1
- Carboxylic Acids: 973
  - Acyclic Acids
    - Valerates: 135
      - (1-(hydroxymethyl)-4-(4-methyl-3-(methylethyl)pentylidene)-3-oxo-2-oxolanyl)methyl 4-methyl-3-(methylethyl)pentanoate: 1
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Valerates: 135
      - (1-(hydroxymethyl)-4-(4-methyl-3-(methylethyl)pentylidene)-3-oxo-2-oxolanyl)methyl 4-methyl-3-(methylethyl)pentanoate: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Furans: 85
    - 4-Butyrolactone: 81
      - (1-(hydroxymethyl)-4-(4-methyl-3-(methylethyl)pentylidene)-3-oxo-2-oxolanyl)methyl 4-methyl-3-(methylethyl)pentanoate: 1

Experts

1.	Fuks, Zvi: 1 article (01/2009)
2.	Haimovitz-Friedman, Adriana: 1 article (01/2009)
3.	Kang, Ji-Hye: 1 article (01/2009)
4.	Kolesnick, Richard: 1 article (01/2009)
5.	Lerman, Gabriel: 1 article (01/2009)
6.	Marquez, Victor E: 1 article (01/2009)
7.	Rotenberg, Susan A: 1 article (01/2009)
8.	Truman, Jean-Philip: 1 article (01/2009)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2009 - "Using the LNCaP orthotopic prostate model it is shown that treatment with TPA or DAG-lactone induces significant reduction in tumor ATM levels coupled with tumor growth delay. " 01/01/2009 - "Furthermore, while fractionated radiation alone produces significant tumor growth delay, pretreatment with TPA or DAG-lactone significantly potentiates tumor cure. "
2.	Prostatic Neoplasms (Prostate Cancer) 01/01/2009 - "We previously demonstrated that treatment of human androgen-responsive prostate cancer cell lines LNCaP and CWR22-Rv1 with 12-O-tetradecanoylphorbol 13-acetate (TPA), a known protein kinase C (PKC) activator, decreases ATM protein levels, thus de-repressing the enzyme ceramide synthase (CS) and promoting apoptosis as well as radio-sensitizing these cells.(1) Here we show that PKCalpha mediates the TPA effect on ATM expression, since ATM suppression and apoptosis induced by either TPA or diacylglycerol-lactone (DAG-lactone), both inducing PKCalpha activation,(2) are abrogated in LNCaP cells following transfection of a kinase-dead PKCalpha mutant (KD-PKCalpha). "

Related Drugs and Biologics

1.	Ataxia Telangiectasia Mutated Proteins
2.	Protein Kinase C
3.	Phosphotransferases (Kinase)
4.	Lactones
5.	Enzymes
6.	Diglycerides
7.	Androgens
8.	dihydroceramide desaturase